Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 107
interventional 85
Observational 19
Registry 3

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 34
Drug|placebo 27
Biological 12
Biological|placebo 7
Other 3
Diagnostic Test|Genetic 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 20
United Kingdom 7
Germany 6
Netherlands 6
France 4
Japan 4
NA 2
Netherlands|Romania 2
United States|Canada|Jordan 2
Argentina|Austria|Denmark|France|Germany|Israel|Italy|Spain|Switzerland|United Kingdom 1
Austria|Denmark|France|Germany|Hungary|Israel|Italy|North Macedonia|Poland|Romania|Switzerland|United Kingdom 1
Belgium 1
Bulgaria|Hungary|Poland|Romania 1
Germany|United Kingdom 1
Italy 1
Spain|Switzerland|Australia|Austria|Canada|Denmark|Germany|Hungary|Italy|Macedonia, The Former Yugoslav Republic of|United Kingdom 1
United States|Argentina|Australia|Bulgaria|Canada|Czech Republic|Hungary|Israel|Macedonia, The Former Yugoslav Republic of|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|Canada|Colombia|Germany|Hungary|Israel|Italy|Spain 1
United States|Australia|Austria|Denmark|France|Germany|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|New Zealand|North Macedonia|Poland|Serbia|Slovakia|South Africa|Spain|Switzerland|United Kingdom 1
United States|Australia|Canada|Czechia|Germany|Hungary|Israel|Italy|Romania|Spain|United Kingdom 1
United States|Australia|Canada|Czechia|Hungary|Israel|Italy|Romania|Spain|United Kingdom 1
United States|Australia|Canada|Germany|Israel 1
United States|Australia|Canada|Hungary|Israel|Romania|Russian Federation|South Africa|Ukraine 1
United States|Austria|Canada|Czechia|France|Germany|Hungary|North Macedonia|Romania|Spain|United Kingdom 1
United States|Austria|Czechia|Germany|Hungary|Italy|Netherlands|North Macedonia|Poland|United Kingdom 1
United States|Belgium|Canada|France|Germany|Hungary|Italy|United Kingdom 1
United States|Bulgaria|Canada|Hungary|Israel|Italy|Macedonia, The Former Yugoslav Republic of|Poland|Romania|Serbia|South Africa 1
United States|Canada 1
United States|Canada|Czechia|Italy|Macedonia, The Former Yugoslav Republic of|Romania|Serbia 1
United States|Canada|Germany|Hungary|Israel|Romania|Spain 1
United States|Canada|Germany|Hungary|Spain 1
United States|Canada|Germany|Israel|Italy|Puerto Rico|United Kingdom 1
United States|Canada|Germany|Italy|Jordan|Puerto Rico|United Kingdom 1
United States|Canada|Israel|United Kingdom 1
United States|Czechia|Germany|Hungary|Israel|Italy|Macedonia, The Former Yugoslav Republic of|Poland|Romania|Slovakia 1
United States|Germany 1
United States|Germany|Hungary 1
United States|Germany|Israel|Mexico|Romania 1
United States|Germany|Spain|Sweden 1
United States|Italy|Jordan 1
United States|Netherlands 1

Sites per Study

Site_count Study_Count
1 31
2 4
3 2
4 2
5 1
6 2
7 3
8 4
10 3
11 2
12 1
14 2
16 2
18 1
20 1
22 1
23 1
24 2
25 1
26 2
27 2
30 1
32 1
36 1
37 1
39 1
40 1
41 2
43 1
45 1
47 1
48 1
55 1
64 1
79 1

Phase

Phase Study_Count
Phase 3 33
Phase 2 20
Phase 1 13
N/A 7
Phase 2/Phase 3 6
Phase 4 5
Phase 1/Phase 2 1

Number of Arms

Number_of_Arms Count_of_Studies
1 20
2 34
3 11
4 9
5 2
6 3
10 1
NA 5

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 24.00000 7.00000 18 9.00000 6.0000 8.0000 11.0
1st Qu. 31.00000 20.00000 18 18.00000 29.7500 26.0000 19.0
Median 42.00000 28.00000 18 25.00000 93.5000 85.0000 20.0
Mean 64.85714 39.38462 18 34.89474 134.6667 83.9697 59.2
3rd Qu. 88.00000 48.00000 18 48.50000 122.0000 118.0000 46.0
Max. 150.00000 122.00000 18 77.00000 475.0000 240.0000 200.0

Trial Group Type

group_type Group_Count
Experimental 136
Placebo Comparator 34
Active Comparator 15
Other 9
NA 5
No Intervention 1

Intervention Model

intervention_model Study_Count
Parallel Assignment 40
Single Group Assignment 26
Crossover Assignment 18
NA 1

Primary Purpose

primary_purpose Study_Count
Treatment 55
Prevention 22
NA 5
Basic Science 1
Diagnostic 1
Other 1

Observational Studies

Studies by Country

Country Study_Count
France 4
United States 2
Australia|Austria|Brazil|Czechia|Denmark|France|Germany|Greece|Ireland|Israel|Italy|Spain|Sweden|United Kingdom 1
Austria|Germany|Switzerland|United Kingdom 1
Belgium|France|Germany|Italy|Spain|United Kingdom 1
Bulgaria|Croatia|Czechia|France|Germany|Hungary|Italy|North Macedonia|Norway|Poland|Slovakia|Slovenia|Sweden 1
China 1
Georgia|Romania 1
Germany 1
Italy|Germany|Japan|Poland|Turkey|United Kingdom 1
Japan 1
Netherlands 1
Thailand 1
United States|Canada|Puerto Rico 1
United States|Denmark|Germany|Switzerland 1

Sites per Study

Site_count Study_Count
1 7
2 1
6 1
11 1
14 1
17 1
18 1
20 1
25 1
27 1
40 2
74 1

Enrollment Metrics

Measure Observational
Min 1.000
1st Qu 78.000
Median 120.000
Mean 1812.895
3rd Qu 309.000
Max 23470.000

Observation Model

observational_model Study_Count
Cohort 13
Case-Only 2
Other 2
Case-Control 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 15
Cross-Sectional 1
Other 1
Retrospective 1
NA 1

Registries

Studies by Country

Country Study_Count
France 1
Italy 1
United States 1

Sites per Study

Site_count Study_Count
1 3

Enrollment Metrics

Measure Registries
Min 220.0000
1st Qu 261.5000
Median 303.0000
Mean 507.6667
3rd Qu 651.5000
Max 1000.0000

Registry Model

observational_model Study_Count
Cohort 3

Time Perspective

time_perspective Study_Count
Prospective 3

Follow-up

target_duration Study_Count
1 Year 1
3 Years 1
5 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03240133 Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema https://ClinicalTrials.gov/show/NCT03240133 Completed BioCryst Pharmaceuticals 2019-01-29
NCT03202784 A Relative Bioavailability Study of Two Formulations of BCX7353 https://ClinicalTrials.gov/show/NCT03202784 Completed BioCryst Pharmaceuticals 2017-08-01
NCT03136237 A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions https://ClinicalTrials.gov/show/NCT03136237 Completed BioCryst Pharmaceuticals 2017-08-15
NCT02966314 Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy https://ClinicalTrials.gov/show/NCT02966314 Completed University of Wisconsin, Madison 2020-01-06
NCT02892682 The Role of the Coagulation Pathways in Recurrent Angioedema https://ClinicalTrials.gov/show/NCT02892682 Recruiting University Hospital, Montpellier 2021-05-31
NCT02865720 Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT02865720 Completed Shire 2017-06-23
NCT02819102 An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates https://ClinicalTrials.gov/show/NCT02819102 Completed BioCryst Pharmaceuticals 2016-06-30
NCT02663687 Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects https://ClinicalTrials.gov/show/NCT02663687 Completed Shire 2016-12-05
NCT02586805 Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE https://ClinicalTrials.gov/show/NCT02586805 Completed Shire 2017-04-13
NCT02448264 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers https://ClinicalTrials.gov/show/NCT02448264 Completed BioCryst Pharmaceuticals 2015-11-30
NCT02316353 A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema https://ClinicalTrials.gov/show/NCT02316353 Completed CSL Behring 2017-09-21
NCT02303626 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks https://ClinicalTrials.gov/show/NCT02303626 Completed BioCryst Pharmaceuticals 2016-01-31
NCT02247739 A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor https://ClinicalTrials.gov/show/NCT02247739 Completed Pharming Technologies B.V. 2016-05-31
NCT02218294 Study to Determine How BCX4161 is Metabolized and Eliminated by the Body https://ClinicalTrials.gov/show/NCT02218294 Completed BioCryst Pharmaceuticals 2014-09-30
NCT02125162 A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 https://ClinicalTrials.gov/show/NCT02125162 Completed BioCryst Pharmaceuticals 2014-07-31
NCT02093923 Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects https://ClinicalTrials.gov/show/NCT02093923 Completed Shire 2015-05-31
NCT02052141 Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT02052141 Completed Shire 2017-05-04
NCT02045264 Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers https://ClinicalTrials.gov/show/NCT02045264 Completed Shire 2014-02-28
NCT01984788 Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE https://ClinicalTrials.gov/show/NCT01984788 Completed BioCryst Pharmaceuticals 2014-05-31
NCT01923207 A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects https://ClinicalTrials.gov/show/NCT01923207 Completed Shire 2014-01-07
NCT01919801 Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema https://ClinicalTrials.gov/show/NCT01919801 Completed Shire 2015-08-22
NCT01912456 A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema https://ClinicalTrials.gov/show/NCT01912456 Completed CSL Behring 2015-10-31
NCT01760343 A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor https://ClinicalTrials.gov/show/NCT01760343 Completed CSL Behring 2013-03-31
NCT01756157 Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks https://ClinicalTrials.gov/show/NCT01756157 Completed Shire 2013-09-13
NCT01723072 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy https://ClinicalTrials.gov/show/NCT01723072 Completed Novartis 2014-05-31
NCT01679912 A Call Center During HAE Attacks (SOS HAE) https://ClinicalTrials.gov/show/NCT01679912 Completed Assistance Publique - Hôpitaux de Paris 2016-09-30
NCT01576523 A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route https://ClinicalTrials.gov/show/NCT01576523 Completed CSL Behring 2012-12-31
NCT01467947 Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert https://ClinicalTrials.gov/show/NCT01467947 Completed CSL Behring 2014-10-31
NCT01457430 Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE https://ClinicalTrials.gov/show/NCT01457430 Completed Massachusetts General Hospital 2014-04-30
NCT01426763 A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase https://ClinicalTrials.gov/show/NCT01426763 Completed Shire 2011-11-30
NCT01413542 Pharmacogenetics of Ace Inhibitor-Associated Angioedema https://ClinicalTrials.gov/show/NCT01413542 Completed Vanderbilt University 2013-07-31
NCT01386658 A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT01386658 Completed Shire 2018-03-12
NCT01371877 The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment https://ClinicalTrials.gov/show/NCT01371877 Completed University of Nebraska 2013-09-30
NCT01359969 Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients https://ClinicalTrials.gov/show/NCT01359969 Completed Pharming Technologies B.V. 2017-07-17
NCT04349800 A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers https://ClinicalTrials.gov/show/NCT04349800 Completed KalVista Pharmaceuticals, Ltd. 2018-09-10
NCT04307381 An Extension Study of IONIS-PKK-LRx in Participants With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT04307381 Recruiting Ionis Pharmaceuticals, Inc. 2021-12-06
NCT04208412 A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II https://ClinicalTrials.gov/show/NCT04208412 Recruiting KalVista Pharmaceuticals, Ltd. 2020-09-30
NCT04206605 Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) and Acquired Angioedema (AAE) Due to C1-INH Deficiency https://ClinicalTrials.gov/show/NCT04206605 Active, not recruiting Shire 2023-03-03
NCT04180163 Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT04180163 Recruiting Shire 2021-12-31
NCT04070326 A Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Pediatric Participants of 2 Years to Less Than (<) 12 Years of Age https://ClinicalTrials.gov/show/NCT04070326 Active, not recruiting Shire 2021-12-17
NCT04032002 Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic Angioedema https://ClinicalTrials.gov/show/NCT04032002 Recruiting University Hospital, Rouen 2021-09-30
NCT03917680 Evaluation of New Markers in Type 3 Angioedema https://ClinicalTrials.gov/show/NCT03917680 Completed Brugmann University Hospital 2019-10-08
NCT03888755 A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants https://ClinicalTrials.gov/show/NCT03888755 Completed Shire 2016-02-12
NCT03873116 Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan https://ClinicalTrials.gov/show/NCT03873116 Active, not recruiting BioCryst Pharmaceuticals 2019-11-30
NCT03749135 Dupilumab in Chronic Spontaneous Urticaria https://ClinicalTrials.gov/show/NCT03749135 Recruiting Charite University, Berlin, Germany 2020-10-31
NCT03545464 COrticosteroids in acUte uRticAria in emerGency dEpartment https://ClinicalTrials.gov/show/NCT03545464 Recruiting Assistance Publique - Hôpitaux de Paris 2020-11-15
NCT03485911 Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE https://ClinicalTrials.gov/show/NCT03485911 Active, not recruiting BioCryst Pharmaceuticals 2019-04-10
NCT03472040 A Long Term Safety Study of BCX7353 in Hereditary Angioedema https://ClinicalTrials.gov/show/NCT03472040 Recruiting BioCryst Pharmaceuticals 2024-02-29
NCT01188564 Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks https://ClinicalTrials.gov/show/NCT01188564 Completed Pharming Technologies B.V. 2012-12-31
NCT01154361 AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study https://ClinicalTrials.gov/show/NCT01154361 Completed Technische Universität München NA
NCT01095510 CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 https://ClinicalTrials.gov/show/NCT01095510 Completed Shire 2012-04-17
NCT01095497 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration https://ClinicalTrials.gov/show/NCT01095497 Completed Shire 2010-12-31
NCT01005888 C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks https://ClinicalTrials.gov/show/NCT01005888 Completed Shire 2007-05-31
NCT00997204 EASSI - Evaluation of the Safety of Self-Administration With Icatibant https://ClinicalTrials.gov/show/NCT00997204 Completed Shire 2011-06-30
NCT00914966 A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE https://ClinicalTrials.gov/show/NCT00914966 Completed Shire 2012-05-31
NCT00912093 A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) https://ClinicalTrials.gov/show/NCT00912093 Completed Shire 2012-07-31
NCT00890162 A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis https://ClinicalTrials.gov/show/NCT00890162 Completed National Institutes of Health Clinical Center (CC) 2018-07-31
NCT00851409 A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration https://ClinicalTrials.gov/show/NCT00851409 Completed Pharming Technologies B.V. 2010-03-31
NCT02741596 Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE https://ClinicalTrials.gov/show/NCT02741596 Completed Shire 2019-10-31
NCT02870972 Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT02870972 Completed BioCryst Pharmaceuticals 2017-08-31
NCT01826916 EDEMA2: Evaluation of DX-88’s Effect in Mitigating Angioedema https://ClinicalTrials.gov/show/NCT01826916 Completed Shire 2005-12-01
NCT02584959 Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT02584959 Completed Shire 2017-07-24
NCT04030598 A Study to Assess the Clinical Efficacy of IONIS-PKK-LRx in Participants With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT04030598 Recruiting Ionis Pharmaceuticals, Inc. 2020-11-30
NCT03712228 A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT03712228 Active, not recruiting CSL Behring 2021-10-14
NCT00748202 Berinert P Study of Subcutaneous Versus Intravenous Administration https://ClinicalTrials.gov/show/NCT00748202 Completed Johann Wolfgang Goethe University Hospital 2010-12-31
NCT00500656 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT00500656 Completed Shire 2008-03-31
NCT00462709 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks https://ClinicalTrials.gov/show/NCT00462709 Completed Shire 2009-03-31
NCT00456508 Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT00456508 Completed Shire 2010-06-01
NCT00457015 Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT00457015 Completed Shire 2008-06-01
NCT00438815 Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks https://ClinicalTrials.gov/show/NCT00438815 Completed Shire 2009-03-31
NCT00432510 Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects https://ClinicalTrials.gov/show/NCT00432510 Completed Shire 2007-03-31
NCT00385372 Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria https://ClinicalTrials.gov/show/NCT00385372 Completed University Hospital Muenster 2007-01-31
NCT00292981 C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) https://ClinicalTrials.gov/show/NCT00292981 Completed CSL Behring 2010-02-28
NCT00289211 C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks https://ClinicalTrials.gov/show/NCT00289211 Completed Shire 2006-12-31
NCT00262301 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT00262301 Completed Pharming Technologies B.V. 2009-07-31
NCT00262288 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT00262288 Completed Pharming Technologies B.V. 2007-01-31
NCT00262080 Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT00262080 Completed Shire 2005-12-31
NCT00261053 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT00261053 Completed Pharming Technologies B.V. 2005-09-30
NCT00225147 Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT00225147 Completed Pharming Technologies B.V. 2009-10-31
NCT00168103 Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks https://ClinicalTrials.gov/show/NCT00168103 Completed CSL Behring 2007-10-31
NCT00125541 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema https://ClinicalTrials.gov/show/NCT00125541 Completed Sanquin Plasma Products BV 2008-04-30
NCT00125151 C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema https://ClinicalTrials.gov/show/NCT00125151 Completed Sanquin Plasma Products BV NA
NCT00119431 Kinetics, Efficacy and Safety of C1-Esteraseremmer-N https://ClinicalTrials.gov/show/NCT00119431 Completed Sanquin Plasma Products BV NA
NCT00097695 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema https://ClinicalTrials.gov/show/NCT00097695 Completed Shire 2008-03-31
NCT00004694 Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations https://ClinicalTrials.gov/show/NCT00004694 Completed FDA Office of Orphan Products Development NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04130191 Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT04130191 Recruiting Shire 2024-04-30
NCT03845400 Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE) https://ClinicalTrials.gov/show/NCT03845400 Recruiting Shire 2023-09-30
NCT03029728 Biomarker for Hereditary AngioEdema Disease https://ClinicalTrials.gov/show/NCT03029728 Recruiting Centogene AG Rostock 2023-12-31
NCT02854397 Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population https://ClinicalTrials.gov/show/NCT02854397 Recruiting University Hospital, Grenoble 2020-08-31
NCT01034969 Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) https://ClinicalTrials.gov/show/NCT01034969 Recruiting Shire 2023-05-24
NCT04091113 Hereditary Angioedema Kininogen Assay https://ClinicalTrials.gov/show/NCT04091113 Recruiting Centogene AG Rostock 2020-09-01
NCT01541423 A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema https://ClinicalTrials.gov/show/NCT01541423 Completed Shire 2016-09-30
NCT01397864 C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks https://ClinicalTrials.gov/show/NCT01397864 Recruiting Pharming Technologies B.V. 2021-06-30
NCT01338363 Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists https://ClinicalTrials.gov/show/NCT01338363 Completed AstraZeneca 2015-08-31
NCT03558009 Epidemiological Analysis for Hereditary Angioedema Disease https://ClinicalTrials.gov/show/NCT03558009 Recruiting Centogene AG Rostock 2022-06-30
NCT04057131 FIRAZYR General Drug Use-Results Survey (Japan) https://ClinicalTrials.gov/show/NCT04057131 Recruiting Shire 2022-11-23
NCT03849625 Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand https://ClinicalTrials.gov/show/NCT03849625 Recruiting Chulalongkorn University 2020-06-30
NCT03656939 A Safety Study For Prevenar 13 Among Chinese Children https://ClinicalTrials.gov/show/NCT03656939 Active, not recruiting Pfizer 2020-09-30
NCT01108848 Patient Registry Study of Berinert® in Normal Clinical Practice https://ClinicalTrials.gov/show/NCT01108848 Completed CSL Behring 2014-04-30
NCT01059526 Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema https://ClinicalTrials.gov/show/NCT01059526 Completed Shire 2013-09-01
NCT00876369 Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema https://ClinicalTrials.gov/show/NCT00876369 Completed University of Nebraska 2009-12-31
NCT03240991 Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon’s Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK) https://ClinicalTrials.gov/show/NCT03240991 Completed Centre Hospitalier Universitaire de Besancon 2016-12-01
NCT02833675 Determination of Specific Biomarkers of Angioneurotic Crisis https://ClinicalTrials.gov/show/NCT02833675 Completed University Hospital, Grenoble 2017-08-31
NCT02826356 Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema https://ClinicalTrials.gov/show/NCT02826356 Completed Hospices Civils de Lyon 2016-03-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03845946 CLOUD-R HAE REGISTRY https://ClinicalTrials.gov/show/NCT03845946 Recruiting University Hospital, Grenoble 2028-09-01
NCT03828279 Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II https://ClinicalTrials.gov/show/NCT03828279 Recruiting HAE Global Registry Foundation 2019-12-31
NCT03697187 Patient Registry to Evaluate the Real-world Safety of Ruconest® https://ClinicalTrials.gov/show/NCT03697187 Recruiting Pharming Technologies B.V. 2021-07-16